Terms: = Brain cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
58 results:
1. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract] [Full Text] [Related]
2. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract] [Full Text] [Related]
3. The identification of BCL-XL and mcl-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
[TBL] [Abstract] [Full Text] [Related]
4. Central nervous system involvement by mantle cell lymphoma.
McLaughlin N; Wang Y; Witzig T; Villasboas J; Habermann T; Inwards D; Bennani N; Thanarajasingam G; Nowakowski G; Porrata L; Thompson C; Micallef I; Johnston P; Ansell S; Paludo J
Leuk Lymphoma; 2023 Feb; 64(2):371-377. PubMed ID: 36416595
[TBL] [Abstract] [Full Text] [Related]
5. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract] [Full Text] [Related]
6. Ursolic acid enhances the antitumor effects of sorafenib associated with mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer.
Li H; Yu Y; Liu Y; Luo Z; Law BYK; Zheng Y; Huang X; Li W
Pharmacol Res; 2022 Aug; 182():106306. PubMed ID: 35714823
[TBL] [Abstract] [Full Text] [Related]
7. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics.
Koessinger AL; Cloix C; Koessinger D; Heiland DH; Bock FJ; Strathdee K; Kinch K; Martínez-Escardó L; Paul NR; Nixon C; Malviya G; Jackson MR; Campbell KJ; Stevenson K; Davis S; Elmasry Y; Ahmed A; O'Prey J; Ichim G; Schnell O; Stewart W; Blyth K; Ryan KM; Chalmers AJ; Norman JC; Tait SWG
Cell Death Differ; 2022 Oct; 29(10):2089-2104. PubMed ID: 35473984
[TBL] [Abstract] [Full Text] [Related]
8. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
[TBL] [Abstract] [Full Text] [Related]
9. brain-Targeted Codelivery of Bcl-2/Bcl-xl and mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy.
He W; Li X; Morsch M; Ismail M; Liu Y; Rehman FU; Zhang D; Wang Y; Zheng M; Chung R; Zou Y; Shi B
ACS Nano; 2022 Apr; 16(4):6293-6308. PubMed ID: 35353498
[TBL] [Abstract] [Full Text] [Related]
10. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
[TBL] [Abstract] [Full Text] [Related]
11. SD-36 promotes growth inhibition and induces apoptosis via suppression of mcl-1 in glioma.
Kong S; Ge X; Li X; Liu Z; Zhang R; Yang M; Wang Z; Li Z
J Cell Mol Med; 2021 Sep; 25(17):8261-8270. PubMed ID: 34291563
[TBL] [Abstract] [Full Text] [Related]
12. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
[TBL] [Abstract] [Full Text] [Related]
13. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C
Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Zhong C; Kayamori K; Koide S; Shinoda D; Oshima M; Nakajima-Takagi Y; Nagai Y; Mimura N; Sakaida E; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Yamaguchi K; Furukawa Y; Lennox W; Sheedy J; Weetall M; Iwama A
Cancer Sci; 2020 Dec; 111(12):4336-4347. PubMed ID: 33037737
[TBL] [Abstract] [Full Text] [Related]
15. Pimozide Suppresses the Growth of brain Tumors by Targeting STAT3-Mediated Autophagy.
Ranjan A; Kaushik I; Srivastava SK
Cells; 2020 Sep; 9(9):. PubMed ID: 32971907
[TBL] [Abstract] [Full Text] [Related]
16. Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis.
Nantavithya C; Paulino AC; Liao K; McGovern SL; Grosshans DR; McAleer MF; Woodhouse KD; Khatua S; Chintagumpala MM; Majd NK; Yeboa DN
Pediatr Blood Cancer; 2020 Aug; 67(8):e28373. PubMed ID: 32453481
[TBL] [Abstract] [Full Text] [Related]
17. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
[TBL] [Abstract] [Full Text] [Related]
18. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract] [Full Text] [Related]
20. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract] [Full Text] [Related]
[Next]